TNNT2

Quality 0.50 · 1 view · Updated 2 months ago

Protein-coding gene in the species Homo sapiens

title: "TNNT2" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public description: "Protein-coding gene in the species Homo sapiens" topic_path: "uncategorized" source: "https://en.wikipedia.org/wiki/TNNT2" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Protein-coding gene in the species Homo sapiens ::

::figure[src="https://upload.wikimedia.org/wikipedia/commons/7/7f/Cardiac_sarcomere_structure.png" caption="Cardiac sarcomere structure, featuring troponin T"] ::

Cardiac muscle troponin T (cTnT) is a protein that in humans is encoded by the TNNT2 gene. Cardiac TnT is the tropomyosin-binding subunit of the troponin complex, which is located on the thin filament of striated muscles and regulates muscle contraction in response to alterations in intracellular calcium ion concentration.

The TNNT2 gene is located at 1q32 in the human chromosomal genome, encoding the cardiac muscle isoform of troponin T (cTnT). Human cTnT is an ~36-kDa protein consisting of 297 amino acids including the first methionine with an isoelectric point (pI) of 4.88. It is the tropomyosin- binding and thin filament anchoring subunit of the troponin complex in cardiac muscle cells. TNNT2 gene is expressed in vertebrate cardiac muscles and embryonic skeletal muscles.

Structure

Cardiac TnT is a 35.9 kDa protein composed of 298 amino acids. Cardiac TnT is the largest of the three troponin subunits (cTnT, troponin I (TnI), troponin C (TnC)) on the actin thin filament of cardiac muscle. The structure of TnT is asymmetric; the globular C-terminal domain interacts with tropomyosin (Tm), TnI and TnC, and the N-terminal tether which strongly binds Tm. The N-terminal region of TnT is alternatively spliced, accounting for multiple isoforms observed in cardiac muscle.

Function

As part of the Troponin complex, the function of cTnT is to regulate muscle contraction. The N-terminal region of TnT that strongly binds actin most likely moves with Tm and actin during strong myosin crossbridge binding and force generation. This region is likely involved in the transduction of cooperativity down the thin filament. The C-terminal region of TnT constitutes part of the globular troponin complex domain, and participates in employing the calcium sensitivity of strong myosin crossbridge binding to the thin filament.

Clinical significance

Mutations in this gene have been associated with familial hypertrophic cardiomyopathy as well as with restrictive and dilated cardiomyopathy. Transcripts for this gene undergo alternative splicing that results in many tissue-specific isoforms, however, the full-length nature of some of these variants has not yet been determined. Mutations of this gene may be associated with mild or absent hypertrophy and predominant restrictive disease, with a high risk of sudden cardiac death. Advancement to dilated cardiomyopathy may be more rapid in patients with TNNT2 mutations than in those with myosin heavy chain mutations.

In patients with active chronic non-inflammatory myopathy and myositis, skeletal muscles are a significant source of cardiac troponin T without any cardiac involvement. It is advised to measure cardiac troponin I instead if a skeletal muscle disorder is suspected.

;Elevated levels after COVID-19 mRNA vaccinations A study carried out by the University of Basel and the University Hospital of Basel found that a COVID-19 mRNA vaccination significantly elevates the cardiac troponin T levels in the blood stream. 3% of the study subjects have shown elevated amounts of the protein after their 3rd vaccination. The effect was most pronounced among young men. It is not yet clear what the mechanism is, and the observed troponin levels were still much lower than in clinically significant heart disease. Given that previous studies only registered 35 cases of heart muscle inflammation per million subjects, the involved researchers were surprised by the results.

Evolution

::figure[src="https://upload.wikimedia.org/wikipedia/commons/4/49/TnT_TnI_gene_pairs.jpg"] ::

Three homologous genes have evolved in vertebrates encoding three muscle type- specific isoforms of TnT. Each of the TnT isoform genes is linked in chromosomal DNA to a troponin I (TnI) isoform gene encoding the inhibitory subunit of the troponin complex to form three gene pairs: The fast skeletal muscle TnI (fsTnI)-fsTnT, slow skeletal muscle TnI (ssTnI)-cTnT, and cTnI-ssTnT pairs. Sequence and epitope conservation studies suggested that genes encoding the muscle type-specific TnT and TnI isoforms have originated from a TnI-like ancestor gene and duplicated and diversified from a fsTnI-like-fsTnT-like gene pair. ::figure[src="https://upload.wikimedia.org/wikipedia/commons/d/d9/TNNT2_gene_phylogenic_tree.jpg"] ::

The apparently scrambled linkage between ssTnI-cTnT and cTnI-ssTnT genes actually reflects original functional linkages as that TNNT2 gene is expressed together with ssTnI gene in embryonic cardiac muscle. Protein sequence alignment demonstrated that TNNT2 gene is conserved in vertebrate species (Fig. 2) in the middle and C-terminal regions, while the three muscle type isoforms are significantly diverged.

Alternative splicing

Mammalian TNNT2 gene contains 14 constitutive exons and 3 alternatively spliced exons. Exons 4 and 5 encoding the N-terminal variable region and exon 13 between the middle and C-terminal regions are alternatively spliced. Exon 5 encodes a 9 or 10 amino acid segment that is highly acidic and negatively charged at physiological pH. Exon 5 is expressed in embryonic heart, down-regulated and ceases express during postnatal development.

Embryonic cTnT with more negative charge at the N-terminal region exerts higher calcium sensitivity of actomyosin ATPase activity and myofilament force production, compared with the adult cardiac TnT, as well as a higher tolerance to acidosis.

TNNT2 gene is transiently expressed in embryonic and neonatal skeletal muscles in both avian and mammalian organisms. When TNNT2 is expressed in neonatal skeletal muscle, the alternative splicing of exon 5 exhibits a synchronized regulation to that in the heart in a species-specific manner. This phenomenon indicates that alternative splicing of TNNT2 pre-mRNA is under the control of a genetically built- in systemic biological clock.

Posttranslational modifications

Phosphorylation

Ser2 of cTnT at the N terminus is constitutively phosphorylated by unknown mechanisms. cTnT has been found to be phosphorylated by PKC at Thr197, Ser201, Thr206, Ser208 and Thr287 in the C-terminal region. Phosphorylation of Thr206 alone was sufficient to reduce myofilament calcium sensitivity and force production. cTnT is also phosphorylated at Thr194 and Ser198 under stress conditions, leading to attenuated cardiomyocyte contractility. Phosphorylation of cTnT at Ser278 and Thr287 by ROCK-II was shown to decrease myosin ATPase activity and myofilament force development in skinned cardiac muscle. Table 1 summarizes the phosphorylation modifications of cTnT and possible functions.

O-linked GlcNAcylation

cTnT is increasingly modified at Ser190 by O-GlcNAcylation during the development of heart failure in rat, accompanied by decreased phosphorylation of Ser208.

Proteolytic modification

In apoptotic cardiomyocytes, cTnT was cleaved by caspase 3 to generate a 25-kDa N-terminal truncated fragment. This destructive fragmentation removes a part of the middle region tropomyosin binding site 1, leading to attenuation of the myofilament force production by decreasing the myosin ATPase activity.

In cardiac muscle under stress conditions, cardiac TnT is cleaved by calpain I, restrictively removing the entire N-terminal variable region. This proteolytic modification of cTnT occurs in cardiac muscle in acute ischemia-reperfusion or pressure overload.

The restrictively N-terminal truncated cTnT remains functional in the myofilaments and leads to reduced contractile velocity of the ventricular muscle, which extends the rapid ejection phase and results in an increase in stroke volume, especially under increased afterload. In vitro studies showed that N-terminal truncated cTnT preserved the overall cardiac myofilament calcium sensitivity and cooperativity, but altered TnT's binding affinities for tropomyosin, TnI and TnC proteins, and lead to slightly decreased maximum myosin ATPase activity and myofilament force production, which forms the basis of the selective decrease in contractile velocity of ventricular muscle to increase stroke volume without significant increase in energy expenditure.

With the relatively short half-life of cTnT in cardiomyocytes (3–4 days), the N-terminal truncated cTnT would be replaced by newly synthesized intact cTnT in several days. Therefore, this mechanism provides a reversible posttranslational regulation to modulate cardiac function in adaptation to stress conditions.

::data[format=table title="'''Phosphorylation sites in cTnT in comparison with ssTnT and fsTnT'''"]

Phosphorylation siteKinaseFunctionReferencecTnTssTnTfsTnT
Ser2ccPKCUnknown
Thr197nNPKCNo functional effect
Ser201nnPKCNo functional effect
Thr204nnPKCReduce Myosin ATPase activity, myofilament force production and Ca2+ sensitivity
Thr204nnCaMK IIUnknown
Thr204nnASK IReduce cardiomyocyte contractility
Thr206PKCReduce Ca2+ sensitivity, actomyosin ATPase activity and tension development
Ser208nnPKCReduce Myosin ATPase activity, alter myofilament Ca2+ sensitivity
Ser208nnASK IReduce cardiomyocyte contractility
Thr213ccPKCReduce Myosin ATPase activity, myofilament force production and Ca2+ sensitivity
Thr213ccRaf-1Unknown
Ser285ncPKCReduce Myosin ATPase activity, myofilament force production and Ca2+ sensitivity
Ser285ncROCK-IIReduce myofilament force development, Myosin ATPase activity and Ca2+ sensitivity
Thr294nnPKCReduce Myosin ATPase activity, myofilament force production and Ca2+ sensitivity
Thr294nnROCK-IIReduce myofilament force development, myosin ATPase activity and Ca2+ sensitivity
::

The residues in cardiac TnT with phosphorylation regulations are summarized. The residue numbers for phosphorylatable serine and threonine are that in human cardiac TnT with the first methionine included. The phosphorylation of cardiac TnT at these residues is compared with the counterparts in fast TnT and slow TnT. C, conserved; N, non-conserved. Kinases responsible for each phosphorylation, functional effects, and references are also listed.

Mutations in cardiomyopathies

Point mutations in TNNT2 gene cause various types of cardiomyopathies, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and restrictive cardiomyopathy (RCM). The table below summarizes representative TNNT2 mutations and abnormal splicings found in human and animal cardiomyopathies.

::data[format=table title="'''Representative TNNT2 mutations and abnormal splicings that cause cardiomyopathy'''"]

MutationDiagnosisReference
Ile79AsnHCM
Arg92GlnHCM
Intron 16G1→A (D14 and D28+7)HCM
Arg92LeuHCM
Arg92TrpHCM
Arg94LeuHCM
Arg94CysHCM
ΔE96RCM
Ala104ValHCM
Phe110IleDCM
Arg130CysHCM
Arg131TrpDCM
E136KRCM
Arg141TrpDCM
DGlu160HCM
Glu163ArgHCM
Glu163LysHCM
Ser179PheHCM
Arg205LeuDCM
DLys210DCM
Glu244AspHCM
Asp270AsnDCM
Lys273GluDCM
Arg278CysHCM
::

Amino Acid residues of mutations were numbered as in human cardiac TnT with the first methionine included. Mutations of cardiac TnT that caused cardiomyopathies were mostly found in the conserved middle and C-terminal regions.

Notes

| wikidate = 2015 | journal = Gene | title = | vauthors = Wei B, Jin JP | date = | volume = | issue = | pages = | doi = | pmid = | pmc =

References

References

  1. "Entrez Gene: TNNT2 troponin T type 2 (cardiac)".
  2. (June 2022). "Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T". Circulation.
  3. (2022-11-10). "Corona-Booster wirkt häufiger aufs Herz als erwartet". Swiss Radio and Television SRF.
  4. (Nov 1991). "Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle". Circulation Research.
  5. (Feb 2007). "Troponin T core structure and the regulatory NH2-terminal variable region". Biochemistry.
  6. (May 2009). "To investigate protein evolution by detecting suppressed epitope structures". Journal of Molecular Evolution.
  7. (Apr 2002). "Functional consequences of caspase activation in cardiac myocytes". Proceedings of the National Academy of Sciences of the United States of America.
  8. (Sep 1985). "A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing". The Journal of Biological Chemistry.
  9. "Troponin T, cardiac muscle". Cardiac Organellar Protein Atlas Database.
  10. (Jul 2015). "Interplay between troponin T phosphorylation and O-N-acetylglucosaminylation in ischaemic heart failure". Cardiovascular Research.
  11. (Jun 1998). "Genomic organisation, alternative splicing and polymorphisms of the human cardiac troponin T gene". Journal of Molecular and Cellular Cardiology.
  12. (Jul 2008). "Restricted N-terminal truncation of cardiac troponin T: a novel mechanism for functional adaptation to energetic crisis". The Journal of Physiology.
  13. (Dec 1996). "Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy". Circulation.
  14. (May 2001). "Cardiac troponin T Arg92Trp mutation and progression from hypertrophic to dilated cardiomyopathy". Clinical Cardiology.
  15. (Jan 2002). "A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy". The American Journal of Cardiology.
  16. (June 2025). "Micro-calpain is essential for postmortem proteolysis of muscle proteins". Journal of Animal Science.
  17. (1998). "A rapid protocol for cardiac troponin T gene mutation detection in familial hypertrophic cardiomyopathy". Human Mutation.
  18. (Jul 1983). "Some properties of cardiac troponin T structure". The Biochemical Journal.
  19. (Feb 2002). "Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy". Journal of Cardiac Failure.
  20. (Feb 2000). "Functional consequences of the deletion mutation deltaGlu160 in human cardiac troponin T". Journal of Biochemistry.
  21. (Jul 2003). "ASK1 associates with troponin T and induces troponin T phosphorylation and contractile dysfunction in cardiomyocytes". The American Journal of Pathology.
  22. (Aug 2009). "Clinical and functional characterization of TNNT2 mutations identified in patients with dilated cardiomyopathy". Circulation: Cardiovascular Genetics.
  23. (Apr 1995). "A site phosphorylated in bovine cardiac troponin T by cardiac CaM kinase II". Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology.
  24. (Sep 1996). "Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties". The Journal of Biological Chemistry.
  25. (2006). "Dephosphorylation specificities of protein phosphatase for cardiac troponin I, troponin T, and sites within troponin T". International Journal of Biological Sciences.
  26. (Aug 1989). "Isolation and characterization of cDNA clones encoding embryonic and adult isoforms of rat cardiac troponin T". The Journal of Biological Chemistry.
  27. (Oct 1992). "Complete nucleotide sequence and structural organization of rat cardiac troponin T gene. A single gene generates embryonic and adult isoforms via developmentally regulated alternative splicing". Journal of Molecular Biology.
  28. (Aug 1996). "Alternative RNA splicing-generated cardiac troponin T isoform switching: a non-heart-restricted genetic programming synchronized in developing cardiac and skeletal muscles". Biochemical and Biophysical Research Communications.
  29. (2008). "Isoform diversity, regulation, and functional adaptation of troponin and calponin". Critical Reviews in Eukaryotic Gene Expression.
  30. (Dec 2000). "Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy". The New England Journal of Medicine.
  31. (Nov 2008). "Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes". Heart.
  32. (2005). "Calcium, thin filaments, and the integrative biology of cardiac contractility". Annual Review of Physiology.
  33. (Oct 2008). "Cardiac thin filament regulation". Pflügers Archiv.
  34. (Dec 1996). "Clinical manifestations of hypertrophic cardiomyopathy with mutations in the cardiac beta-myosin heavy chain gene or cardiac troponin T gene". Journal of Cardiac Failure.
  35. (Oct 2001). "Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy". Circulation.
  36. (Jun 1996). "Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy". The Journal of Clinical Investigation.
  37. (Dec 2003). "Cardiac troponin T mutation R141W found in dilated cardiomyopathy stabilizes the troponin T-tropomyosin interaction and causes a Ca2+ desensitization". Journal of Molecular and Cellular Cardiology.
  38. (Jul 1997). "Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility". Circulation Research.
  39. (Jan 1981). "Turnover of cardiac troponin subunits. Kinetic evidence for a precursor pool of troponin-I". The Journal of Biological Chemistry.
  40. (Aug 2005). "Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype". The Journal of Biological Chemistry.
  41. (Nov 2004). "Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy". Journal of the American College of Cardiology.
  42. (Mar 2001). "Transgenic incorporation of skeletal TnT into cardiac myofilaments blunts PKC-mediated depression of force". American Journal of Physiology. Heart and Circulatory Physiology.
  43. (Mar 1997). "Sudden death due to troponin T mutations". Journal of the American College of Cardiology.
  44. (Jul 1999). "Functional consequences of a carboxyl terminal missense mutation Arg278Cys in human cardiac troponin T". Biochemical and Biophysical Research Communications.
  45. (Feb 1997). "Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy". Journal of Molecular and Cellular Cardiology.
  46. (Sep 1999). "Effects of missense mutations Phe110Ile and Glu244Asp in human cardiac troponin T on force generation in skinned cardiac muscle fibers". Journal of Biochemistry.
  47. (Nov 1992). "Protein kinase C phosphorylation of cardiac troponin T decreases Ca2+-dependent actomyosin MgATPase activity and troponin T binding to tropomyosin-F-actin complex". The Biochemical Journal.
  48. (Dec 1989). "Identification of sites phosphorylated in bovine cardiac troponin I and troponin T by protein kinase C and comparative substrate activity of synthetic peptides containing the phosphorylation sites". The Journal of Biological Chemistry.
  49. (Nov 2001). "Disease-causing mutations in cardiac troponin T: identification of a critical tropomyosin-binding region". Biophysical Journal.
  50. (Jul 1991). "Deletion of the first 45 NH2-terminal residues of rabbit skeletal troponin T strengthens binding of troponin to immobilized tropomyosin". The Journal of Biological Chemistry.
  51. (May 2006). "Infantile restrictive cardiomyopathy resulting from a mutation in the cardiac troponin T gene". Pediatrics.
  52. (Aug 1998). "Troponin T: genetics, properties and function". Journal of Muscle Research and Cell Motility.
  53. (2009). "Raf-1: a novel cardiac troponin T kinase". Journal of Muscle Research and Cell Motility.
  54. (Jan 2008). "A troponin T mutation that causes infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development and impairs the inhibitory properties of troponin". The Journal of Biological Chemistry.
  55. (October 2023). ["Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression"](http://blues.sabinet.co.za/WebZ/Authorize?sessionid=0:autho=pubmed:password=pubmed2004&/AdvancedQuery?&format=F&next=images/ejour/cardio1/cardio1_v18_n3_a4.pdf }}{{Dead link). Cardiovascular Journal of Africa.
  56. (2014). "Gene regulation, alternative splicing, and posttranslational modification of troponin subunits in cardiac development and adaptation: a focused review". Frontiers in Physiology.
  57. (Nov 2003). "Autopsy findings in siblings with hypertrophic cardiomyopathy caused by Arg92Trp mutation in the cardiac troponin T gene showing dilated cardiomyopathy-like features". Clinical Cardiology.
  58. (Oct 1988). "Effects of acidosis on ventricular muscle from adult and neonatal rats". Circulation Research.
  59. (Oct 2013). "Posttranslational modifications of cardiac troponin T: an overview". Journal of Molecular and Cellular Cardiology.
  60. (Sep 2003). "Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T". The Journal of Biological Chemistry.
  61. (Aug 2009). "Impact of cardiac troponin T N-terminal deletion and phosphorylation on myofilament function". Biochemistry.
  62. (Jun 1994). "Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere". Cell.
  63. (May 1994). "Human cardiac troponin T: identification of fetal isoforms and assignment of the TNNT2 locus to chromosome 1q". Genomics.
  64. (May 1983). "Isoform variants of troponin in skeletal and cardiac muscle cells cultured with and without nerves". Cell.
  65. (Apr 2005). "Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin". Circulation Research.
  66. (Dec 2002). "Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy". Circulation.
  67. (Nov 1999). "A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy". Heart.
  68. (Jul 1981). "Purification and properties of dog cardiac troponin T kinase". The Journal of Biological Chemistry.
  69. (Apr 1995). "Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy". The New England Journal of Medicine.
  70. (Jan 2011). "Troponin T isoforms and posttranscriptional modifications: Evolution, regulation and function". Archives of Biochemistry and Biophysics.
  71. (Sep 2006). "Selective deletion of the NH2-terminal variable region of cardiac troponin T in ischemia reperfusion by myofibril-associated mu-calpain cleavage". Biochemistry.
  72. (Jul 2011). "Phosphorylation, but not alternative splicing or proteolytic degradation, is conserved in human and mouse cardiac troponin T". Biochemistry.
  73. (Oct 2013). "Integration of cardiac proteome biology and medicine by a specialized knowledgebase". Circulation Research.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::